Day One Biopharmaceuticals (NASDAQ:DAWN) PT Raised to $36.00 at JPMorgan Chase & Co.

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price target hoisted by equities researchers at JPMorgan Chase & Co. from $32.00 to $36.00 in a report released on Monday, Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 116.35% from the company’s current price.

A number of other research firms have also recently weighed in on DAWN. Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. The Goldman Sachs Group cut their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $39.83.

Day One Biopharmaceuticals Stock Up 8.2 %

NASDAQ:DAWN opened at $16.64 on Monday. The company has a market capitalization of $1.45 billion, a PE ratio of -6.99 and a beta of -1.48. Day One Biopharmaceuticals has a 52-week low of $9.67 and a 52-week high of $17.85. The stock has a fifty day simple moving average of $15.27 and a 200-day simple moving average of $13.78.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). As a group, equities analysts anticipate that Day One Biopharmaceuticals will post -2.66 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Samuel C. Blackman sold 2,258 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the sale, the insider now directly owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CFO Charles N. York II sold 2,666 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $40,656.50. Following the completion of the sale, the chief financial officer now directly owns 277,754 shares of the company’s stock, valued at approximately $4,235,748.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Samuel C. Blackman sold 2,258 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the sale, the insider now directly owns 1,244,662 shares of the company’s stock, valued at $18,981,095.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,781 shares of company stock valued at $883,160. Corporate insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in DAWN. First Turn Management LLC purchased a new stake in shares of Day One Biopharmaceuticals during the 4th quarter worth about $24,834,000. TimesSquare Capital Management LLC lifted its holdings in Day One Biopharmaceuticals by 45.8% in the 4th quarter. TimesSquare Capital Management LLC now owns 1,666,065 shares of the company’s stock worth $24,325,000 after purchasing an additional 523,455 shares during the last quarter. Braidwell LP lifted its holdings in Day One Biopharmaceuticals by 13.5% in the 4th quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock worth $61,547,000 after purchasing an additional 500,000 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Day One Biopharmaceuticals by 28.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock worth $30,935,000 after purchasing an additional 472,654 shares during the last quarter. Finally, Superstring Capital Management LP acquired a new stake in Day One Biopharmaceuticals in the 4th quarter worth approximately $5,543,000. 87.95% of the stock is owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.